Kinnate Biopharma
Focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically-defined cancers. Learn more
Launch date
Employees
Market cap
€114m
Enterprise valuation
(€23m) (Public information from Apr 2024)
Share price
$2.65 KNTE
San Diego California (HQ)
Authorizing premium user...